Geroscience T32 Positions Available for Pre- and Post-doctoral Fellows
The Geroscience T32 NIH training program currently supports 3 post-doctoral fellows and 5 graduate students with research interests in the field of geroscience. The goal of the program is to offer training and mentorship to young investigators to significantly advance their careers in fields related to geroscience and aging research. The program focuses on the interaction between biological aging and disease (aging as a risk factor for disease). These areas include, but are not limited to, mechanisms of brain aging (including Alzheimer’s Disease), neurodegeneration, cellular senescence, neuronal glycolysis, caloric restriction, oxidative stress, molecular biology of aging, mitochondria dysfunction, genomics, metabolomics, sarcopenia, and gero-oncology. See attached document for additional information.
Applications are due Friday, October 18th at 5:00pm.
Oklahoma Nathan Shock Center: Pilot Award Opportunity
Description: The Oklahoma Nathan Shock Center is soliciting applications to support the research of early-stage investigators, and senior investigators initiating new research programs in aging/geroscience, that can serve as the base for the development of new applications for NIA funding. The projects should utilize services provided by the Oklahoma Nathan Shock Center Cores as described on the NSC website (
oklahomanathanshockcenteronaging.org). The awards range from $5,000 to $20,000 depending on the specific needs of the applicant. Applications from outside the University of Oklahoma Health Sciences, the Oklahoma Medical Research Foundation, and the Oklahoma City VA Health Care system, as well as collaborative projects with other Nathan Shock Centers are strongly encouraged.
Deadline for Submission: October 18, 2024
Link to the Full Announcement: Please see attached (Oklahoma Nathan Shock Pilot 2024)
2025 OK-INBRE Research Project Investigator Awards – Request for Proposals
Deadline: October 31, 2024
The Oklahoma IDeA Network for Biomedical Research Excellence (OK-INBRE) is soliciting applications for its Research Project Investigator (RPI) award program. The purpose of the RPI program is to foster and develop biomedical research programs designed to generate preliminary data that enhances the competitiveness of the investigator for future extramural funding. Full-time, tenure track faculty members (or equivalent) at the University of Oklahoma Health Sciences or the Oklahoma Medical Research Foundation who qualify as an Early-Stage Investigator as defined by the NIH are eligible to apply. Awarded projects will receive up to $100,000 in direct costs per year plus applicable F&A costs for up of two years. The forms, instructions, and submission information can be found on the
OK-INBRE website. Questions regarding this OK-INBRE funding opportunity can be directed to
okinbre@ouhsc.edu or Dr. Mark Lang at
mark-lang@ouhsc.edu.
Presbyterian Health Foundation (PHF) Bridge Grant Program – Request for Applications
Cycle I PHF Bridge Grant Program Deadline: Monday, October 21, 2024
The primary objective of the PHF Bridge Grant Program is to provide funding to enhance OUHSC faculty competitiveness for extramural funding. OUHSC Principal Investigators are eligible if they meet the following criteria: 1) have submitted an extramural application within the past 18 months that was scored but not funded, 2) are requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs; and 3) received a review that ranks applications and provides critiques. This program can now provide funding for up to
$75,000 for one year. Guidelines and Application Form are attached or can be found at
https://research.ouhsc.edu/research-administration/grants/funding-opportunities/phf-funding. If you have any questions, please email
VPR@ouhsc.edu.
Presbyterian Health Foundation (PHF) Technology Advancement Grant (TAG) Program – Request For Applications
Cycles I-III PHF TAG Grant Program Deadline: ROLLING APPLICATIONS
The TAG program replaces the Equipment grant program. The primary objective of the PHF TAG program is to provide partial funding for critically needed research equipment that could be transformative for the research mission at OUHSC. This program is fully aligned with Pillar 1 of the Strategic Plan. The TAG program will proactively and with the help of a committee address campus-wide needs and fill critical gaps, with the goals to grow the research enterprise, expand innovative technology and research infrastructure, and promote addition of new cutting-edge technology on campus. Funding priority will be given to research equipment that will permit OUHSC investigators to be more competitive for external funding and provides support to multiple users. Funds may be used for equipment to be purchased as part of a recruitment package for new faculty or for equipment to support the research of current faculty. If the funds will be used for a new recruit, the recruit must have signed the offer letter with a specific start date or specific start date time frame. Equipment and/or technology funded by PHF is expected to be made available to all researchers at OUHSC, whenever possible. All OUHSC Assistant, Associate, or Full Professors are eligible to apply. Applicants are required to match requested funds. The maximum allowable budget for this program is $500,000 (PHF funding: $250,000; Applicant funding: $250,000). The minimum allowable budget for this program is $60,000 (PHF funding: $30,000; Applicant funding: $30,000). Only one application will be accepted per investigator per year.
New Clinical Study Opportunities
***************************************************
Please note this is NOT a solicitation for study subjects
***************************************************
Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:
-
European Myeloma Network - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
-
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
-
This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (6 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation
-
Pfizer - Request for Proposals (RFP) Education for Patients and Caregivers Living With Bladder Cancer from Non-Muscle Invasive Bladder Cancer (NMIBC) to Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
-
Pfizer - Request for Proposals (RFP) PARP-Inhibitor Combination Treatments: Safety and Efficacy in a rapidly changing metastatic Castration Resistant Prostate Cancer (mCRPC) landscape
-
Pfizer - Request for Proposals (RFP) Clinical Data Updates and Treatment Management Strategies in First-line ALK-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
-
Pfizer Request for Proposals (RFP) Education in the Era of Emerging Hemophilia Therapy
-
Pfizer - Request for Proposals (RFP) Clinical Data Updates and Treatment Management Strategies in First-line ALK-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
-
Pfizer - Request for Proposals (RFP) ncrease Awareness & Understanding of Emerging Hemophilia Treatment Options
-
Pfizer Independent Medical Education Request for Proposals USP <797> Pharmaceutical Compounding-Sterile Preparations: Ensuring Compliance Now and For the Future
Please contact Scott Davis at
scott-davis@ouhsc.edu if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.